These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24418710)

  • 1. Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs.
    Kanamaru C; Yamada Y; Hayashi S; Matsushita T; Suda A; Nagayasu M; Kimura K; Chiba S
    J Toxicol Sci; 2014 Feb; 39(1):59-69. PubMed ID: 24418710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.
    Zhou D; Liu Y; Ye J; Ying W; Ogawa LS; Inoue T; Tatsuta N; Wada Y; Koya K; Huang Q; Bates RC; Sonderfan AJ
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):401-9. PubMed ID: 24090817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 as a Potential Therapeutic Target in Retinal Disease.
    Aguilà M; Cheetham ME
    Adv Exp Med Biol; 2016; 854():161-7. PubMed ID: 26427407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90.
    Kitson RR; Chang CH; Xiong R; Williams HE; Davis AL; Lewis W; Dehn DL; Siegel D; Roe SM; Prodromou C; Ross D; Moody CJ
    Nat Chem; 2013 Apr; 5(4):307-14. PubMed ID: 23511419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
    Lancet JE; Gojo I; Burton M; Quinn M; Tighe SM; Kersey K; Zhong Z; Albitar MX; Bhalla K; Hannah AL; Baer MR
    Leukemia; 2010 Apr; 24(4):699-705. PubMed ID: 20111068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
    Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
    J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells.
    Toyomura K; Saito T; Emori S; Matsumoto I; Kato E; Kaneko M; Okuma Y; Nakamura H; Murayama T
    J Toxicol Sci; 2012; 37(5):1049-57. PubMed ID: 23038012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.
    Bruserud Ø; Hatfield KJ; Reikvam H
    Leuk Res; 2011 Sep; 35(9):1156-8. PubMed ID: 21802728
    [No Abstract]   [Full Text] [Related]  

  • 18. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
    Blagg BS; Kerr TD
    Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
    Neckers L
    Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.